Concord Biotech Board Approves Q2 FY27 Unaudited Financial Results

Concord Biotech Limited's Board of Directors has approved the unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The Board also fixed November 4, 2026, as the record date for the allotment of bonus equity shares. Additionally, the company announced the reconstitution of its Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee. The statutory auditors, BSR & Co. LLP, have issued their Limited Review Reports on the financial results.